WO2018115475A3 - Zusammensetzung enthaltend n-acetyldiaminobuttersäure - Google Patents

Zusammensetzung enthaltend n-acetyldiaminobuttersäure Download PDF

Info

Publication number
WO2018115475A3
WO2018115475A3 PCT/EP2017/084454 EP2017084454W WO2018115475A3 WO 2018115475 A3 WO2018115475 A3 WO 2018115475A3 EP 2017084454 W EP2017084454 W EP 2017084454W WO 2018115475 A3 WO2018115475 A3 WO 2018115475A3
Authority
WO
WIPO (PCT)
Prior art keywords
containing composition
acetyldiaminobutyric acid
acetyldiaminobutyric
acid
composition
Prior art date
Application number
PCT/EP2017/084454
Other languages
English (en)
French (fr)
Other versions
WO2018115475A2 (de
Inventor
Andreas Bilstein
Original Assignee
Bitop Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bitop Ag filed Critical Bitop Ag
Priority to CN201780087060.3A priority Critical patent/CN110461321A/zh
Priority to EP17872888.7A priority patent/EP3558287A2/de
Priority to MX2019007490A priority patent/MX2019007490A/es
Priority to US16/472,624 priority patent/US20190380985A1/en
Priority to BR112019012788A priority patent/BR112019012788A2/pt
Publication of WO2018115475A2 publication Critical patent/WO2018115475A2/de
Publication of WO2018115475A3 publication Critical patent/WO2018115475A3/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/021Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/021Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/007Preparations for dry skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biophysics (AREA)
  • Birds (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Die Erfindung betrifft eine Zusammensetzung enthaltend N- Acetyldiaminobuttersäure, ein Salz oder einen Ester von N- Acetyldiaminobuttersäure zur Anwendung in einem Verfahren zur Behandlung des menschlichen oder tierischen Körpers.
PCT/EP2017/084454 2016-12-22 2017-12-22 Zusammensetzung enthaltend n-acetyldiaminobuttersäure WO2018115475A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN201780087060.3A CN110461321A (zh) 2016-12-22 2017-12-22 含有n-乙酰基二氨基丁酸的组合物
EP17872888.7A EP3558287A2 (de) 2016-12-22 2017-12-22 Zusammensetzung enthaltend n-acetyldiaminobuttersäure
MX2019007490A MX2019007490A (es) 2016-12-22 2017-12-22 Composicion que contiene acido n-acetildiamino butirico.
US16/472,624 US20190380985A1 (en) 2016-12-22 2017-12-22 Composition Containing N-acetyldiaminobutyric Acid
BR112019012788A BR112019012788A2 (pt) 2016-12-22 2017-12-22 composição contendo ácido n-acetildiaminobutírico

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102016125414.2 2016-12-22
DE102016125414.2A DE102016125414A1 (de) 2016-12-22 2016-12-22 Zusammensetzung enthaltend N-Acetyldiaminobuttersäure

Publications (2)

Publication Number Publication Date
WO2018115475A2 WO2018115475A2 (de) 2018-06-28
WO2018115475A3 true WO2018115475A3 (de) 2018-08-23

Family

ID=62186383

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/084454 WO2018115475A2 (de) 2016-12-22 2017-12-22 Zusammensetzung enthaltend n-acetyldiaminobuttersäure

Country Status (7)

Country Link
US (1) US20190380985A1 (de)
EP (1) EP3558287A2 (de)
CN (1) CN110461321A (de)
BR (1) BR112019012788A2 (de)
DE (1) DE102016125414A1 (de)
MX (1) MX2019007490A (de)
WO (1) WO2018115475A2 (de)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003714A2 (en) * 1991-08-27 1993-03-04 The Upjohn Company Method for treatment of metabolic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10262084B4 (de) 2002-05-17 2009-12-24 Dr. Franz Köhler Chemie GmbH Protektive Lösung zur Verhinderung von Ischämieschäden
DE10330243A1 (de) 2003-07-03 2005-01-20 bitop Aktiengesellschaft für biotechnische Optimierung Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von Arzneimitteln zur äusserlichen Behandlung der Neurodermitis
DE102006056766A1 (de) 2006-12-01 2008-06-05 Bitop Ag Verwendung von kompatiblen Soluten
WO2010006792A1 (de) 2008-07-16 2010-01-21 Bitop Ag Synthese von zyklischen amidinen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003714A2 (en) * 1991-08-27 1993-03-04 The Upjohn Company Method for treatment of metabolic disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CÁNOVAS D ET AL: "Role of Ngamma-acetyldiaminobutyrate as an enzyme stabilizer and an intermediate in the biosynthesis of hydroxyectoine", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 65, no. 9, 1 September 1999 (1999-09-01), pages 3774 - 3779, XP002253695, ISSN: 0099-2240 *
RONQUIST G ET AL: "Antitumor activity of L-2,4 diaminobuturic acid against mouse fibrosarcoma cells in vitro and in vivo.", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 1980, vol. 96, no. 3, 1980, pages 259 - 268, XP009506043, ISSN: 0171-5216 *

Also Published As

Publication number Publication date
MX2019007490A (es) 2019-12-11
EP3558287A2 (de) 2019-10-30
BR112019012788A2 (pt) 2019-12-03
US20190380985A1 (en) 2019-12-19
DE102016125414A1 (de) 2018-06-28
WO2018115475A2 (de) 2018-06-28
CN110461321A (zh) 2019-11-15

Similar Documents

Publication Publication Date Title
PH12017501033A1 (en) Oral care compositions and methods of use
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
EP3180009A4 (de) Zoledronsäuredarreichungsformen zur behandlung von schmerzen
EP3778605A3 (de) Lrrk2-inhibitoren und verfahren zur herstellung und verwendung davon
EP4282479A3 (de) Verwendung von pridopidin zur behandlung von depression oder angst
EP4218759A3 (de) Kombinationstherapie
EP3139939A4 (de) Zusammensetzungen und verfahren zur behandlung von haut- und schleimhautmembranerkrankungen
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
EP3233091A4 (de) Hypochlorsäureformulierungen und verfahren zur behandlung von hauterkrankungen
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
EP3949973A3 (de) Zusammensetzungen und verfahren zur behandlung von depression
EP3386556A4 (de) Systeme und verfahren für optimierte patientenspezifische gewebegezüchtete gefässtransplantate
EP3456815A4 (de) Wässrige lösung zur verabreichung an einen lebenden körper und verfahren zur herstellung davon
MX2015015162A (es) Agente de reduccion de acido urico.
PH12017502069A1 (en) Method for treating coffee rust, citrus black spot, citrus scab and banana black sigatoka diseases
MX2017001113A (es) Composicion adhesiva.
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
WO2015156674A3 (en) Method for treating cancer
EP3475442A4 (de) 12(s)-hydroxyeicosatriensäure-verbindungen und deren verwendung als therapeutika
WO2018115475A3 (de) Zusammensetzung enthaltend n-acetyldiaminobuttersäure
GB2550750A (en) Anthelmintic compounds
MX2016017321A (es) Combinacicones y metodos para el tratamiento de dolor neuropatico.
EP3250166A4 (de) Verfahren zur wiederherstellung des ansprechens auf ein medikament in gewebe von lebenden organismen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17872888

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019012788

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2017872888

Country of ref document: EP

Effective date: 20190722

ENP Entry into the national phase

Ref document number: 112019012788

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190619